Effectiveness of a nation-wide COVID-19 vaccination program in Mexico

  title={Effectiveness of a nation-wide COVID-19 vaccination program in Mexico},
  author={Omar Yaxmehen Bello-Chavolla and Neftal{\'i} Eduardo Antonio-Villa and Sergio Iv{\'a}n Vald{\'e}s-Ferrer and Carlos A. Ferm{\'i}n-Mart{\'i}nez and Luisa Fern{\'a}ndez-Chirino and D. Ramirez-Garcia and Javier Mancilla-Galindo and Ashuin Kammar-Garc{\'i}a and Jos{\'e} Alberto Avila-Funes and C. H. Zuniga-Gil and Miguel Garc{\'i}a‐Grimshaw and Santa Elizabeth Ceballos-Liceaga and Guillermo Carbajal-Sandoval and Jairo A. Montes-Gonz{\'a}lez and Christian A. Zaragoza-Jim{\'e}nez and Gabriela Garcia-Rodriguez and Ricardo Cortes-Alcal{\'a} and Gustavo Reyes-Ter{\'a}n and Hugo Lopez-Gatell and Luis Miguel Guti{\'e}rrez-Robledo},
BACKGROUND: Vaccination has been effective in ameliorating the impact of COVID-19. However, estimation of vaccine effectiveness (VE) is still unavailable for some widely used vaccines and underrepresented groups. Here, we report on the effectiveness of a nation-wide COVID-19 vaccination program in Mexico. METHODS: We used a test-negative design within a national COVID-19 surveillance system to assess VE of the BNT162b2, mRNA-12732, Gam-COVID-Vac, Ad5-nCoV, Ad26.COV2.S, ChAdOx1 and CoronaVac… 



The impact of vaccination on COVID-19 outbreaks in the United States

The results indicate that vaccination can have a substantial impact on reducing disease transmission and adverse clinical outcomes, however, with uptake of 40% or less in the population, vaccination is unlikely to completely eliminate the need for non-pharmaceutical interventions.

Effectiveness of Covid-19 Vaccines over a 9-Month Period in North Carolina

All three Covid-19 vaccines had durable effectiveness in reducing the risks of hospitalization and death, although the two mRNA vaccines provided higher levels of protection than Ad26.COV2.S.

Effectiveness of an Inactivated SARS-CoV-2 Vaccine in Chile

The results suggest that the inactivated SARS-CoV-2 vaccine effectively prevented Covid-19, including severe disease and death, a finding that is consistent with results of phase 2 trials of the vaccine.

The Impact of Vaccination on Coronavirus Disease 2019 (COVID-19) Outbreaks in the United States

  • S. MoghadasT. Vilches A. Galvani
  • Medicine
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
  • 2021
It is shown that vaccination can have a substantial impact on mitigating COVID-19 outbreaks, even with limited protection against infection, and continued compliance with nonpharmaceutical interventions is essential to achieve this impact.

Interim Estimates of Vaccine Effectiveness of Pfizer-BioNTech and Moderna COVID-19 Vaccines Among Health Care Personnel — 33 U.S. Sites, January–March 2021

VE of partial and complete vaccination in this population is comparable to that reported from clinical trials and recent observational studies, supporting the effectiveness of mRNA COVID-19 vaccines against symptomatic disease in adults, with strong 2-dose protection.

Protection against SARS-CoV-2 after Covid-19 Vaccination and Previous Infection

Two doses of BNT162b2 vaccine were associated with high short-term protection against SARS-CoV-2 infection; this protection waned considerably after 6 months and infection-acquired immunity boosted with vaccination remained high more than 1 year after infection.

Effectiveness of mRNA vaccines and waning of protection against SARS-CoV-2 infection and severe covid-19 during predominant circulation of the delta variant in Italy: retrospective cohort study

The results support the vaccination campaigns targeting high risk people, those aged ≥60 years, and healthcare workers to receive a booster dose of vaccine six months after the primary vaccination cycle and suggest that timing the booster dose earlier than six months post-primary vaccination cycle might be warranted.

Waning effectiveness of SARS-CoV-2 mRNA vaccines in older adults: a rapid review

Evidence of a decline in vaccine effectiveness against both SARS-CoV-2 infection and severe COVID-19 in older adults among studies which analyzed data up to July-October 2021 is suggested.